These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27452524)

  • 1. CD84 mediates CLL-microenvironment interactions.
    Marom A; Barak AF; Kramer MP; Lewinsky H; Binsky-Ehrenreich I; Cohen S; Tsitsou-Kampeli A; Kalchenko V; Kuznetsov Y; Mirkin V; Dezorella N; Shapiro M; Schwartzberg PL; Cohen Y; Shvidel L; Haran M; Becker-Herman S; Herishanu Y; Shachar I
    Oncogene; 2017 Feb; 36(5):628-638. PubMed ID: 27452524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner.
    Barak AF; Lewinsky H; Perpinial M; Huber V; Radomir L; Kramer MP; Sever L; Wolf Y; Shapiro M; Herishanu Y; Jung S; Becker-Herman S; Shachar I
    Oncogene; 2020 Feb; 39(9):1997-2008. PubMed ID: 31772329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
    Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
    J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD84 is a survival receptor for CLL cells.
    Binsky-Ehrenreich I; Marom A; Sobotta MC; Shvidel L; Berrebi A; Hazan-Halevy I; Kay S; Aloshin A; Sagi I; Goldenberg DM; Leng L; Bucala R; Herishanu Y; Haran M; Shachar I
    Oncogene; 2014 Feb; 33(8):1006-16. PubMed ID: 23435417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
    Lewinsky H; Gunes EG; David K; Radomir L; Kramer MP; Pellegrino B; Perpinial M; Chen J; He TF; Mansour AG; Teng KY; Bhattacharya S; Caserta E; Troadec E; Lee P; Feng M; Keats J; Krishnan A; Rosenzweig M; Yu J; Caligiuri MA; Cohen Y; Shevetz O; Becker-Herman S; Pichiorri F; Rosen S; Shachar I
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33465053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.
    Cuenca M; Sintes J; Lányi Á; Engel P
    Clin Immunol; 2019 Jul; 204():43-49. PubMed ID: 30522694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
    Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
    Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.
    Vangapandu HV; Ayres ML; Bristow CA; Wierda WG; Keating MJ; Balakrishnan K; Stellrecht CM; Gandhi V
    Neoplasia; 2017 Oct; 19(10):762-771. PubMed ID: 28863345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
    Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
    Blood; 2012 May; 119(20):4708-18. PubMed ID: 22474251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.
    Farinello D; Wozińska M; Lenti E; Genovese L; Bianchessi S; Migliori E; Sacchetti N; di Lillo A; Bertilaccio MTS; de Lalla C; Valsecchi R; Gleave SB; Lligé D; Scielzo C; Mauri L; Ciampa MG; Scarfò L; Bernardi R; Lazarevic D; Gonzalez-Farre B; Bongiovanni L; Campo E; Cerutti A; Ponzoni M; Pattini L; Caligaris-Cappio F; Ghia P; Brendolan A
    Nat Commun; 2018 May; 9(1):1787. PubMed ID: 29725010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
    Shen Y; Best OG; Mulligan SP; Christopherson RI
    Leuk Lymphoma; 2018 Aug; 59(8):1927-1937. PubMed ID: 29164976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
    Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
    Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.
    Heinig K; Gätjen M; Grau M; Stache V; Anagnostopoulos I; Gerlach K; Niesner RA; Cseresnyes Z; Hauser AE; Lenz P; Hehlgans T; Brink R; Westermann J; Dörken B; Lipp M; Lenz G; Rehm A; Höpken UE
    Cancer Discov; 2014 Dec; 4(12):1448-65. PubMed ID: 25252690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
    Giannoni P; Cutrona G; Totero D
    Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells.
    Os A; Bürgler S; Ribes AP; Funderud A; Wang D; Thompson KM; Tjønnfjord GE; Bogen B; Munthe LA
    Cell Rep; 2013 Aug; 4(3):566-77. PubMed ID: 23933259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
    Wakim J; Arman E; Becker-Herman S; Kramer MP; Bakos E; Shachar I; Elson A
    Oncogene; 2017 Jun; 36(26):3686-3694. PubMed ID: 28166196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironmental interactions and survival of CLL B-cells.
    Munk Pedersen I; Reed J
    Leuk Lymphoma; 2004 Dec; 45(12):2365-72. PubMed ID: 15621749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD84 Links T Cell and Platelet Activity in Cerebral Thrombo-Inflammation in Acute Stroke.
    Schuhmann MK; Stoll G; Bieber M; Vögtle T; Hofmann S; Klaus V; Kraft P; Seyhan M; Kollikowski AM; Papp L; Heuschmann PU; Pham M; Nieswandt B; Stegner D
    Circ Res; 2020 Sep; 127(8):1023-1035. PubMed ID: 32762491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the chronic lymphocytic leukemia microenvironment in vitro.
    Crassini K; Shen Y; Mulligan S; Giles Best O
    Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.